Antibody-Drug Conjugates (ADCs) are a powerful and promising treatment option for patients. This precision-based therapy approach merges antibody specificity with the potency of cytotoxic drugs, enhancing tumor cell targeting while minimizing damage to healthy tissues. ADCs expand treatment options for various cancers and address unmet needs in oncology. An analytical approach to these complex therapeutics that emphasizes detailed characterization and precision can identify and ensure a consistent, high-quality drug product.
Join our upcoming webinar on ADC characterization strategies, where leading experts from Phenomenex and SCIEX will share their knowledge on advancing ADC research and development.
In this session, we will explore case studies related to in-depth ADC characterization:
- Understand how to analyze ADC structural complexities
- Discuss how Biozen Native RP columns from Phenomenex enable LC-MS analysis, under native conditions, to determine DAR (drug-antibody ratio) values, including relevant isomers, for a variety of intact ADCs
- Learn how the Intabio ZT system from SCIEX leverages icIEF-UV/MS and Electron Activated Dissociation (EAD) peptide mapping for multilevel characterization of conjugation end products